OncoSec Medical Inc Стоимость предприятия

Что обозначает Стоимость предприятия в OncoSec Medical Inc?

Стоимость предприятия OncoSec Medical Inc является N/A

Какое определение для Стоимость предприятия?



Стоимость предприятия является измерением общей рыночной стоимости компании. Она рассчитывается как рыночная капитализация с учётом долга, доли меньшинства и привилегированных акций за вычетом общей суммы денежных средств и их эквивалентов.

It is a sum of claims by all claimants including creditors (secured and unsecured) and shareholders (preferred and common). Enterprise value is one of the fundamental metrics used in business valuation, financial modeling, accounting, portfolio analysis, and risk analysis. Enterprise value is more comprehensive than market capitalization, which only reflects common equity and is considered more representative of a company’s value. Enterprise value reflects the opportunistic nature of business and may change substantially over time because of both external and internal conditions.

Enterprise value can be negative if the company holds abnormally high amounts of cash that is not reflected in the market value of the stock and total capitalization. Cash is subtracted in the calculation because it reduces the net cost to a potential purchaser. The effect applies whether the cash is used to issue dividends or to pay down debt. Value of minority interest is added because it reflects the claim on assets consolidated into the firm in question. Value of associate companies is subtracted because it reflects the claim on assets consolidated into other firms. EV should also include such special components as unfunded pension liabilities, employee stock options, environmental provisions, abandonment provisions, and so on, since they also reflect claims on the company.

Что делает OncoSec Medical Inc?

oncosec is a san diego-based biotechnology company pioneering new technologies to stimulate the body’s immune system to target and attack cancer. through our proprietary technology, we hope to deliver safer and more effective cancer treatments that can provide long-term benefits for patients. our technology, immunopulse™, is designed to enhance the local delivery and uptake of dna-based immune-targeting agents, such as il-12. clinical trials of immunopulse™ il-12 demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. our lead program, immunopulse™ il-12, is currently in phase ii development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. to date, study results have laid the groundwork for the expansion into new dna-encoded therapeutic candidates and tumor indications. we ar